References

The following sources support the claims, history, pharmacology, and harm reduction protocols presented in Altered States: A Field Guide to Your Brain on Drugs. They are organized by chapter in the order they appear in the book.

Chapter 1: Who Are You? — A Biochemical Perspective

• Tsakiris M. The Embodied Self: Dimensions, Coherence and Disorders
  Research on multisensory integration and how body awareness, memory, and cognition combine to generate a sense of self.
• Torrico TJ, Bhimji SS. Thalamus (Neuroanatomy) – StatPearls
  Overview of thalamic anatomy and function as a sensory relay and filtering center.
• Davis M. The role of the amygdala in fear and anxiety (Annual Review of Neuroscience)
  Foundational research on amygdala’s role in pre-conscious emotional processing and fear conditioning.
• Cleveland Clinic Staff Serotonin: What It Is, Function & Levels – Cleveland Clinic
  Clinical overview confirming approximately 90% of serotonin is produced in the gastrointestinal tract.
• Wise RA. Dopamine, learning and motivation (Nature Reviews Neuroscience)
  Key review on dopamine’s role in reward prediction, motivation, and incentive salience.
• Kolb B, Gibb R. Neural plasticity and behavior – sixty years of conceptual advances (J. Neurochem.)
  Review of how experience, substances, and therapeutic interventions reshape neural circuits.
• Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (Neuropsychopharmacology)
  Review of clinical evidence for psychedelic-assisted therapy across multiple conditions.
• Vollenweider FX, Preller KH. How do psychedelics work? (Current Opinion in Psychiatry)
  Explains thalamic gating model of psychedelic action and receptor-level mechanisms.
• Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity (Cell Reports)
  Landmark 2018 study showing LSD, DMT, and DOI promote neuritogenesis, spinogenesis, and synaptogenesis comparable to ketamine.
• Raichle ME. The default mode network in healthy individuals: A systematic review and meta-analysis (Brain Connectivity)
  Marcus Raichle’s foundational work on DMN function and its role in self-referential processing.
• Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (Pharmacological Reviews)
  Describes how psychedelics disrupt the DMN and hierarchical brain processes, producing ego dissolution and altered identity.
• Northoff G, Bermpohl F. Cortical midline structures and the self (Trends in Cognitive Sciences)
  Supports the notion that selfhood is neuroanatomically distributed, especially across midline structures of the brain.
• Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders (Nature Reviews Neuroscience)
  Highlights how serotonin (5-HT2A) receptor activation alters thalamocortical information filtering.
• Mashour GA. Consciousness unbound: toward a paradigm of general anesthesia (Anesthesiology)
  Shows how modulating brain connectivity and neurotransmitter balance shifts states of consciousness.
• Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states (Current Topics in Behavioral Neurosciences)
  Supports how psychedelics modify perception, identity, and memory by disrupting normal integration pathways.
• Doss MK, Považan M, Rosenberg MD, et al. Psychedelics flatten the brain’s energy landscape: evidence from receptor-informed network control theory (Nature Communications)
  Provides evidence that psychedelics reduce the brain’s energy barriers, allowing greater flexibility in mental states.
• Nichols DE. Psychedelics (Pharmacological Reviews)
  A definitive overview of how different psychedelic drugs act on neurotransmitter systems, particularly 5-HT2A and dopamine receptors.
• Yaden DB, et al. Psychedelics and consciousness: Distinctions, challenges, and implications (Neuroscience of Consciousness)
  Discusses the neurochemical and philosophical aspects of how psychedelics affect consciousness.
• Ly C, et al. Psychedelics Promote Structural and Functional Neural Plasticity (Cell Reports)
  Demonstrates how psychedelics promote dendritic growth and synaptic strength.
• de Vos CMH, et al. Effect of psychedelic drugs on personality structure and related variables: A systematic review (Neuroscience & Biobehavioral Reviews)
  Examines how psychedelic-induced neuroplasticity correlates with changes in personality and identity.
• Mishra B, Khan FD, Tiwari A. Computational Attitudes in Counselling Psychology (Clinical Aspects of Neuropharmacology, Wiley)
  Supports computational models of neurotransmitter dynamics and their influence on mood and consciousness.
• Le PH, Upshaw WC, et al. Drug-associated delirium: basic pharmacologic principles and clinical considerations (Advances in Health Research)
  Offers insight into how drugs disrupt consciousness and self-awareness via neurotransmitter interference.

↑ Back to top

Chapter 2: Set & Setting — Packing for Your Trip

• Leary T, Metzner R, Alpert R. The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead
  The foundational text where Leary, Metzner, and Alpert formalized the concept of set and setting.
• National Conference of State Legislatures Drug Overdose Immunity and Good Samaritan Laws – NCSL
  Overview of Good Samaritan laws across all 50 states with specific protections and requirements.
• Schultes RE, Hofmann A, Ratsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers
  Foundational ethnobotany text documenting indigenous ceremonial frameworks for psychoactive plant use worldwide.
• Haijen ECHM, et al. Predicting responses to psychedelics: a prospective study (Frontiers in Pharmacology)
  Demonstrates how openness, absorption, and emotional state predict the intensity and positivity of psychedelic experiences.
• Studerus E, Gamma A, Vollenweider FX. Prediction of psilocybin response in healthy volunteers (PLoS ONE)
  Found that baseline personality traits and expectations significantly impact the subjective effects of psilocybin.
• Hartogsohn I. Set and setting, psychedelics and the placebo response: An extrapharmacological perspective on psychopharmacology (Journal of Psychopharmacology)
  Argues that the psychedelic experience is co-produced by cultural, social, and environmental cues.
• Kettner H, Rosas FE, Timmermann C, et al. Psychedelic communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes (Frontiers in Pharmacology)
  Suggests that supportive group settings enhance psychedelic outcomes and long-term mental health.
• Labate BC, Cavnar C (Eds.). The Therapeutic Use of Ayahuasca (Springer)
  Explores ritual contexts in indigenous and Western settings, confirming that structured ceremonial environments enhance healing.
• Dupuis D. Psychedelics as tools for belief transmission. Set, setting, and suggestion in the ritual use of hallucinogens (Transcultural Psychiatry)
  Shows how set and setting in ritual contexts facilitate the transmission of culturally relevant beliefs during psychedelic experiences.
• Kaelen M, et al. The hidden therapist: Evidence for a central role of music in psychedelic therapy (Psychopharmacology)
  Music functions as a nonverbal guide and modulates emotional trajectory in psychedelic sessions.
• Bonny HL, Pahnke WN. The use of music in psychedelic (LSD) psychotherapy (Journal of Music Therapy)
  One of the earliest clinical reports on music’s role in therapeutic LSD sessions.
• Olson JA, Suissa-Rocheleau L, Lifshitz M, et al. Tripping on nothing: Placebo psychedelics and contextual factors (Psychological Consciousness)
  Demonstrates that placebo psychedelics can induce altered states when set and setting are manipulated.
• Van Elk M, Yaden DB. Pharmacological and extra-pharmacological factors in psychedelic experiences: A retrospective survey (Frontiers in Psychology)
  Finds that non-drug factors like intention and atmosphere explain as much variance in outcomes as dose or compound.

↑ Back to top

Chapter 3: MDMA/MDA — “Ecstasy”/”Molly”

• Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents (Addiction)
  Definitive archival study reconstructing MDMA’s discovery at Merck from original lab documents.
• Shulgin A, Shulgin A. PiHKAL: A Chemical Love Story
  Shulgin’s own account of his work with MDMA and its introduction to therapeutic circles.
• Freudenmann RW et al. A review of the history and pharmacology of MDMA (Int. J. Drug Policy)
  Documents the DEA emergency scheduling of MDMA in 1985 and the contested hearing process.
• Mitchell JM, Ot’alora GM, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (Nature Medicine)
  Phase 3 MAPP2 confirmatory trial showing 71.2% of MDMA-AT participants lost PTSD diagnosis.
• MAPS (Multidisciplinary Association for Psychedelic Studies) Phase 3 Trial Program: MDMA-Assisted Therapy for PTSD
  MAPS documents the August 16, 2017, FDA Breakthrough Therapy Designation.
• FDA / Various news outlets FDA Declines to Approve MDMA-Assisted Therapy for PTSD
  FDA’s decision on the Lykos Therapeutics NDA, citing need for additional evidence.
• de la Torre R, Farre M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition (Therapeutic Drug Monitoring)
  Pharmacological study of MDMA’s mechanism including transporter reversal and triple monoamine release.
• Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of MDMA (Pharmacological Reviews)
  Comprehensive pharmacology review including CYP2D6-mediated metabolism of MDMA to MDA.
• Kimura Y, et al. Inhibitory effect of ginger on CYP enzymes (Drug Metabolism and Disposition)
  In vitro study showing ginger compounds inhibit CYP1A2 and CYP2D6 activity.
• Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasheras B. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity (Neuroreport)
  Landmark 1999 rat study showing ALA fully prevented MDMA-induced serotonin loss and oxidative damage.
• Puerta E, Hervias I, et al. Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice (J. Neurochem.)
  Demonstrated ALA’s mechanism: prevents superoxide generation and increases striatal glutathione levels.
• Alves E, Binienda Z, Carvalho F, et al. Acetyl-L-carnitine provides effective in vivo neuroprotection over MDMA-induced mitochondrial neurotoxicity (Neuroscience)
  First study showing ALCAR pretreatment reduced carbonyl formation, mtDNA deletion, and serotonin loss from MDMA.
• Shankaran M, Yamamoto BK, Gudelsky GA. Ascorbic acid prevents MDMA-induced hydroxyl radical formation and behavioral/neurochemical consequences (Synapse)
  Study showing Vitamin C prevented MDMA-induced free radical production and 5-HT depletion in rat striatum.
• Darvesh AS, Gudelsky GA. Evidence for a role of energy dysregulation in MDMA-induced depletion of brain 5-HT (Brain Research)
  Demonstrated CoQ10 attenuated 5-HT depletion in striatum and hippocampus from MDMA administration.
• Tenorio MCDS, Graciliano NG, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress (Curr. Neuropharmacol.)
  Comprehensive review of NAC’s role as glutathione precursor and its neuroprotective, anti-inflammatory mechanisms.
• Froum S. (DDS) Low magnesium levels and tooth grinding (Perio-Implant Advisory)
  Clinical article linking magnesium deficiency to bruxism and recommending glycinate form for bioavailability.
• Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor (Altern. Med. Rev.)
  Review establishing 5-HTP pharmacology: oral bioavailability, BBB penetration, and serotonin synthesis.
• Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan (Pharmacol. Res.)
  Review discussing peripheral decarboxylase inhibition and 5-HTP’s CNS bioavailability when combined with PDIs.
• Hinz M, Stein A, Uncini T. 5-HTP efficacy and contraindications (Neuropsychiatr. Dis. Treat.)
  Critical review on 5-HTP risks, including catecholamine depletion from unbalanced supplementation.
• Mahoney CR, Castellani J, et al. Tyrosine supplementation mitigates working memory decrements during cold exposure (Physiol. Behav.)
  Study on L-tyrosine’s role as catecholamine precursor and its cognitive benefits under neurotransmitter stress.
• RollSafe.org contributors MDMA Supplements Guide (RollSafe.org community reference)
  Community harm reduction resource compiling research on MDMA supplement protocols including antacid use.
• Reiter RJ, Mayo JC, Tan DX, et al. Melatonin: an established antioxidant worthy of use in clinical trials (Mol. Med.)
  Review of melatonin’s dual role as circadian regulator and potent antioxidant with neuroprotective properties.
• Benzenhoefer RW, Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin (Addiction)
  Peer-reviewed reconstruction from Shulgin’s lab notebooks confirming the 1976 synthesis and 1977 introduction to Zeff.
• Feduccia AA, Jerome L, Yazar-Klosinski B, et al. MDMA and MDMA-Assisted Therapy (American Journal of Psychiatry)
  AJP review documenting Zeff’s role in training 150 therapists and treating 4,000+ patients before scheduling.
• Passie T, Dennis A. The History of MDMA (Oxford University Press)
  Oxford Academic history documenting MDMA’s entry into Dallas nightlife and Clegg’s role in branding it ‘Ecstasy.’
• Mayo Clinic Staff Serotonin Syndrome – Symptoms and Causes (Mayo Clinic)
  Clinical reference for serotonin syndrome symptoms, causes, and risk factors.
• Gouzoulis-Mayfrank E, et al. Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database (Front. Psychiatry)
  FDA adverse event database analysis finding zero SS cases from MDMA alone; all 20 cases involved co-administration.
• Foong AL, Grindrod KA, et al. Demystifying serotonin syndrome (or serotonin toxicity) (Can. Fam. Physician)
  Clinical review with infographic on SS risk stratification and severity-based management.
• Feduccia AA, Jerome L, et al. MDMA and MDMA-Assisted Therapy (American Journal of Psychiatry)
  AJP review documenting SSRIs’ protective/blocking effects on MDMA pharmacodynamics.
• Volpi-Abadie J, Kaye AM, Kaye AD. Drug-Induced Serotonin Syndrome (US Pharmacist)
  Clinical review listing DXM as a serotonin reuptake inhibitor capable of causing SS in combination with serotonergic drugs.
• Rosenson J, Smollin C, et al. Ecstasy (MDMA) and water intoxication: clinical features and risk factors (QJM)
  Clinical review of MDMA-associated hyponatremia cases and risk factors including excessive water consumption.
• Liechti ME. Modern clinical research on MDMA (Ecstasy) (Pharmacology & Therapeutics)
  Confirms MDMA’s action on serotonin, dopamine, oxytocin, and potential in treating PTSD and anxiety disorders.
• Mithoefer MC, et al. The safety and efficacy of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD (Journal of Psychopharmacology)
  Landmark MAPS-sponsored study showing significant symptom reduction in treatment-resistant PTSD.
• Doblin R. A Clinical Plan for MDMA (Ecstasy) in the Treatment of PTSD: Partnering with the FDA (Journal of Psychoactive Drugs)
  Foundational MAPS document outlining the clinical roadmap for MDMA-assisted therapy.
• Parrott AC. Human psychobiology of MDMA or ‘Ecstasy’: An overview of 25 years of empirical research (Human Psychopharmacology)
  Extensive review of neurotoxicity, long-term effects, and serotonin system changes from MDMA.
• Hysek CM, et al. MDMA enhances emotional empathy and prosocial behavior (Social Cognitive and Affective Neuroscience)
  Validates the empathogen classification with behavioral neuroscience data.
• Danforth AL, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults (Journal of Psychopharmacology)
  Expands MDMA’s potential beyond PTSD to social anxiety in autism spectrum populations.
• Sessa B. Why MDMA therapy for alcohol use disorder? (Neuropharmacology)
  Suggests MDMA-assisted therapy as a disruptor for addiction treatment models.
• Grob CS, et al. Psychobiologic effects of MDMA in humans: Methodological considerations and preliminary observations (Behavioral and Brain Sciences)
  Early, careful human studies supporting methodological rigor in MDMA trials.
• Karageorgiou J, Milani R. MDMA-assisted psychotherapy: A systematic review of neurobiological mechanisms and therapeutic effects (Frontiers in Psychiatry)
  Neuroimaging and mechanistic evidence supporting therapeutic use of MDMA.
• Nichols DE. Differences between the mechanisms of action of MDMA, MDA, and related substances (Pharmacology Biochemistry and Behavior)
  Biochemical basis for empathogenic and stimulant properties; key differences between MDMA and MDA mechanisms.

↑ Back to top

Chapter 4: Nitrous Oxide — “Whippits”

• Science History Institute The History of Nitrous Oxide – Science History Institute
  Historical record of Priestley’s synthesis of nitrous oxide.
• Davy H. Humphry Davy: Researches, Chemical and Philosophical, Chiefly Concerning Nitrous Oxide (1800)
  Davy’s own published experiments and proposal for anesthetic use of nitrous oxide.
• American Dental Association / Historical sources Horace Wells – Dentist and Pioneer of Anesthesia
  Documents Wells’ 1844 dental extraction under nitrous oxide anesthesia.
• Bhatt DK, Bhatt SR. Nitrous oxide: an old drug, a new mechanism of action? (CNS Drug Reviews)
  Review of nitrous oxide’s NMDA receptor antagonism and dissociative mechanism.
• Sanders RD, Weimann J, Maze M. Nitrous oxide and vitamin B12 (British Journal of Anaesthesia)
  Clinical review of B-12 inactivation mechanism and neurological consequences of chronic nitrous use.
• Ankar A, Kumar A. Vitamin B12 (Cobalamin) – StatPearls
  Clinical reference on B-12 forms, absorption routes, and methylcobalamin’s bioavailability advantages.
• Sanders RD, Weimann J, Maze M. Nitrous oxide and vitamin B12 (Br. J. Anaesth.)
  Review of nitrous oxide’s impact on B-12-dependent methylation and the role of methionine in these pathways.
• Bhatt DK, Bhatt SR, et al. Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide (Biological Psychiatry)
  Describes N2O’s dopamine release via mesolimbic pathway and partial opioid receptor agonism mediating euphoria.
• Zuniga JR, Joseph SA, et al. Does nitrous oxide induce release of brain opioid peptides? (Pharmacology Biochemistry and Behavior)
  Rat study demonstrating N2O-induced release of methionine-enkephalin in cerebrospinal fluid, confirming opioid mechanism.
• Oomen PP, van Dijk M, et al. Mechanisms Involved in the Neurotoxicity and Abuse Liability of Nitrous Oxide (Int. J. Mol. Sci.)
  Comprehensive review of N2O abuse mechanisms: opioid release and NMDA antagonism both disinhibit dopamine.
• Suruda AJ, McGlothlin JD. Asphyxial deaths from the recreational use of nitrous oxide (J. Forensic Sciences)
  Forensic study of 5 N2O deaths plus literature review confirming oxygen displacement as primary death mechanism.
• Yang T, et al. Nitrous oxide exerts rewarding effect via regulating D1 receptor and BDNF pathway (Translational Psychiatry)
  2025 study mapping N2O’s reward mechanism through BDNF/TrkB signaling in the VTA-NAc dopamine circuit.

↑ Back to top

Chapter 5: Cocaine

• Mortimer WG (original 1901); various ethnobotanical sources History of Coca: The ‘Divine Plant’ of the Incas
  Ethnobotanical and historical documentation of traditional coca leaf use in the Andes.
• Niemann A. (original 1860); various pharmacology texts Cocaine – History and Pharmacology
  Niemann’s 1860 isolation and characterization of cocaine from coca leaf.
• Freud S. Uber Coca (On Coca, 1884)
  Freud’s own published advocacy for cocaine’s therapeutic uses.
• Pendergrast M. For God, Country, and Coca-Cola: The Definitive History of the Great American Soft Drink
  History of Coca-Cola’s original coca-leaf formulation and its removal of cocaine.
• Various investigative reports Stepan Company’s legal coca processing for Coca-Cola
  Documents the unique legal arrangement for coca leaf importation and processing.
• Pennings EJM, Leccese AP, de Wolff FA. Cardiovascular Risks of Simultaneous Use of Alcohol and Cocaine – A Systematic Review (J. Clin. Med.)
  Systematic review documenting the 18-25x sudden death risk associated with cocaethylene.
• Richards JR, Le JK. Cocaine (StatPearls – Pharmacology)
  Clinical pharmacology reference for cocaine’s dopamine reuptake inhibition mechanism.
• Larocque A, Hoffman RS. Levamisole-adulterated cocaine: a review of an emerging adulterant (Ann. Emerg. Med.)
  Clinical review of levamisole contamination in cocaine and its immunosuppressive effects.
• Various authors / clinical pharmacology references Tyrosine for the treatment of phenylketonuria / dopamine precursor review (Cochrane Database)
  Evidence for L-tyrosine as dopamine/norepinephrine precursor supporting recovery from catecholamine depletion.
• Dyall SC. Omega-3 fatty acids and their role in central nervous system (Int. J. Mol. Sci.)
  Review of omega-3s’ anti-inflammatory, neuroprotective, and mood-stabilizing effects in the CNS.
• U.S. Sentencing Commission / Various legal sources Fair Sentencing Act of 2010 / Crack-Powder Sentencing Disparity
  Legislative and policy history of the 100:1 crack-to-powder sentencing ratio and its racial disparities.

↑ Back to top

Chapter 6: LSD — “Acid”

• Hofmann A. LSD: My Problem Child
  Hofmann’s own account of synthesizing LSD-25 on November 16, 1938.
• Hofmann A. LSD: My Problem Child
  Hofmann’s documented account of the first intentional LSD experience.
• Kim K, Che T, Panova O, et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor (Cell)
  Structural study showing how LSD’s binding conformation explains its long duration of action.
• Carhart-Harris RL, Muthukumaraswamy S, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging (PNAS)
  Landmark neuroimaging study showing LSD’s effects on brain connectivity and DMN suppression.
• CIA / U.S. Senate Select Committee on Intelligence (Church Committee, 1975) Project MKUltra – Declassified CIA Documents
  Declassified records and Senate investigations documenting MK-Ultra’s LSD experiments.
• U.S. Congress / DEA Controlled Substances Act of 1970
  Federal legislation placing LSD in Schedule I.
• Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? (Drug and Alcohol Dependence)
  Clinical review establishing HPPD as a rare but recognized condition.
• Traini E, Bramanti V, Amenta F. Alpha-GPC and CDP-choline bioavailability and cholinergic activity (Pharmacol. Res.)
  Comparative review of choline forms showing alpha-GPC and CDP-choline superiority for brain bioavailability.
• Dishotsky NI, Loughman WD, Mogar RE, Lipscomb WR. LSD and genetic damage (Science)
  1971 Science review concluding pure LSD in moderate doses does not cause chromosomal damage, mutation, or teratogenic effects.
• Wacker D, Wang S, McCorvy JD, et al. Crystal structure of an LSD-bound human serotonin receptor (Cell)
  First crystal structure of LSD bound to 5-HT2B receptor, revealing the EL2 lid mechanism explaining LSD’s long duration.
• Petri G, Expert P, et al. Homological scaffolds of brain functional networks (J. Royal Society Interface)
  Topological analysis showing LSD produces novel cross-network connectivity patterns not seen in normal brain states.
• Gasser P, Holstein D, Michel Y, et al. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease (J. Nervous and Mental Disease)
  First controlled study in 40+ years showing LSD-assisted psychotherapy reduces anxiety in patients with life-threatening illness.

↑ Back to top

Chapter 7: Psilocybin Mushrooms

• Metzner R. (editor); various ethnobotanical sources Teonanacatl: Sacred Mushroom of Vision
  Ethnographic documentation of Aztec and Mesoamerican ceremonial mushroom use.
• Wasson RG. Seeking the Magic Mushroom (Life Magazine, 1957)
  Wasson’s famous Life magazine photo essay that introduced psilocybin mushrooms to the West.
• Hofmann A, Heim R, Brack A, et al. Psilocybin and psilocin: the chemistry and pharmacology (Experientia)
  Hofmann’s isolation and synthesis of psilocybin and psilocin from Psilocybe mexicana.
• Passie T, Seifert J, Schneider U, Emrich HM. Psilocybin: pharmacology and mechanism of action (Pharmacology & Therapeutics)
  Pharmacological review of psilocybin’s metabolism to psilocin and 5-HT2A partial agonism.
• Carhart-Harris RL, Bolstridge M, et al. Psilocybin with psychological support for treatment-resistant depression (Lancet Psychiatry)
  Clinical trial demonstrating psilocybin’s effects on DMN and treatment-resistant depression.
• State of Oregon / State of Colorado Oregon Psilocybin Services Act (Measure 109) / Colorado Proposition 122
  Legislation establishing legal frameworks for supervised psilocybin therapy.
• Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology (Mycological Research)
  Pharmacological distinction between muscimol-containing Amanita and psilocybin-containing species.
• Leary T, Alpert R, Metzner R, Pahnke WN. Harvard Psilocybin Project (Wikipedia / primary sources)
  Overview of the Harvard experiments, methodology, results, and subsequent controversy.
• Doblin R. Dr. Leary’s Concord Prison Experiment: a 34-year follow-up study (J. Psychoactive Drugs)
  Rick Doblin’s follow-up study showing original recidivism claims were flawed but affirming need for comprehensive post-release support.
• Pahnke WN (under supervision of Leary T). Marsh Chapel Experiment (1962) / Good Friday Experiment
  Documentation of the double-blind psilocybin experiment and 25-year follow-up confirming lasting mystical significance.
• McKenna T. Food of the Gods: The Search for the Original Tree of Knowledge
  McKenna’s 1992 book presenting the speculative theory linking psilocybin to human cognitive evolution.
• U.S. Congress / United Nations Controlled Substances Act (1970) / UN Convention on Psychotropic Substances (1971)
  Legislative history of psilocybin prohibition at federal and international levels.
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety (J. Psychopharmacol.)
  Landmark Johns Hopkins trial showing psilocybin reduced depression and anxiety in cancer patients at 6-month follow-up.
• Rinaudo M. Chitin and Chitosan: Chemistry, Properties and Applications (J. Sci. Ind. Res.)
  Biochemistry reference confirming chitin as a structural component of fungal cell walls that is indigestible by humans.
• Various harm reduction sources / PsychonautWiki Lemon Tek: acid-base extraction of psilocybin (community pharmacology)
  Community-documented technique based on acid-catalyzed dephosphorylation of psilocybin to psilocin.
• Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors (BBRC)
  Study confirming beta-carboline MAO inhibitors in tobacco smoke; effects are from combustion products, not nicotine itself.
• Hong SW, et al. A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke (NeuroToxicology)
  Comprehensive review identifying 38 MAO inhibitor compounds in tobacco smoke across 9 chemical classes.

↑ Back to top

Chapter 8: Ketamine

• Domino EF. Ketamine: history, pharmacology, mechanism of action, and clinical applications (Anesthesiology)
  Historical account of ketamine’s synthesis and development as an anesthetic.
• Li L, Vlisides PE. Ketamine in War and Peace (Anesth Analg.)
  Documents ketamine’s first widespread use in Vietnam War field medicine.
• Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression (Arch. Gen. Psychiatry)
  Landmark trial demonstrating ketamine’s rapid antidepressant effects via NMDA/AMPA pathway.
• U.S. Food and Drug Administration FDA approves new nasal spray medication for treatment-resistant depression (FDA News Release)
  FDA approval announcement for esketamine (Spravato) nasal spray.
• Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. Ketamine-associated urinary tract dysfunction (BJU Int.)
  Clinical documentation of ketamine-induced cystitis and urological damage from chronic use.
• Various urological research Protective effect of N-acetylcysteine on ketamine-induced cystitis (Int. J. Urol.)
  Research on NAC’s role in mitigating ketamine-induced urological damage through antioxidant mechanisms.
• Li L, Vlisides PE. Ketamine in War and Peace (J. Anesth. Hist.)
  Historical account of ketamine adoption for field surgery in Vietnam due to its wide safety margin.
• Morgan CJA, Curran HV. Ketamine use: a review (Addiction)
  Review of ketamine’s recreational emergence, international scheduling history, and patterns of misuse.
• Murrough JW, Perez AM, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions (Biol. Psychiatry)
  Clinical study demonstrating rapid antidepressant response from repeated low-dose ketamine infusions.
• Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine’s Mechanism of Action: A Path to Rapid-Acting Antidepressants (Biol. Psychiatry)
  Comprehensive review of ketamine’s dual GO/STOP pathway model for rapid antidepressant effects via BDNF and synaptogenesis.
• Kang HJ, et al. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review (Frontiers in Psychiatry)
  Systematic review of 139 publications confirming AMPAR, mTOR, BDNF/TrkB as key mediators of ketamine’s rapid antidepressant action.
• Domino EF. Ketamine: 50 years of modulating the mind (Frontiers in Human Neuroscience)
  First-person historical account by Edward Domino, who conducted early ketamine human trials, detailing its development.

↑ Back to top

Chapter 9: DMT/Ayahuasca

• Frecska E, Bokor P, Winkelman M. Ayahuasca: pharmacology, neuroscience and therapeutic potential (Brain Research Bulletin)
  Review of ayahuasca composition, pharmacology, and the MAOI-DMT interaction.
• Szara S. Dimethyltryptamine: its metabolism in man; the relation of its psychotic effect to the serotonin metabolism (Experientia)
  Szara’s pioneering 1956 self-experiment with DMT and first clinical documentation of its effects.
• Strassman R. DMT: The Spirit Molecule
  Strassman’s account of his government-funded DMT research at UNM, published in 2000.
• Barker SA. A critical review of reports of endogenous psychedelic N,N-dimethyltryptamines in humans (J. Psychopharmacol.)
  Review of evidence for endogenous DMT production in the human body.
• Uthaug MV, et al. 5-MeO-DMT: an overview (Drug and Alcohol Dependence)
  Documentation of 5-MeO-DMT in Sonoran Desert toad venom and its psychoactive properties.
• Fontanilla D, Bhatt A, et al. N,N-dimethyltryptamine and the sigma-1 receptor (Mol. Psychiatry)
  Research demonstrating DMT’s activity at the sigma-1 receptor.
• Frecska E, Bokor P, Winkelman M. Ayahuasca: pharmacology, neuroscience and therapeutic potential (Brain Res. Bull.)
  Review of the pharmacological interaction between DMT and MAO inhibitors in the ayahuasca brew.
• Various clinical pharmacology sources Tyramine and MAO inhibitors: foods to avoid (various clinical pharmacology references)
  Clinical pharmacology reference on tyramine-MAOI interaction and dietary restrictions during MAOI therapy.
• Chaves C, dos Santos RG, et al. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics (Front. Psychiatry)
  2024 review of DMT’s unique pharmacological profile including sigma-1, TAAR1, and intracellular 5-HT2A mechanisms.
• Davis AK, Clifton JM, Weaver EG, et al. Survey of entity encounter experiences occasioned by inhaled DMT (J. Psychopharmacology)
  Johns Hopkins survey of 2,561 respondents documenting phenomenology of DMT entity encounters and lasting belief changes.
• Timmermann C, Roseman L, et al. DMT Models the Near-Death Experience (Frontiers in Psychology)
  Imperial College study demonstrating overlap between DMT-induced states and NDE phenomenology on validated scales.
• Luan LX, Eckernas E, et al. Psychological and physiological effects of extended DMT (J. Psychopharmacology)
  First extended IV DMT infusion study showing sustained psychedelic states with controllable intensity via dose titration.

↑ Back to top

Appendices

• Various harm reduction research Fentanyl test strip shelf life and sensitivity (Drug and Alcohol Dependence)
  DanceSafe resource on fentanyl test strip usage, sourcing, and effectiveness data.

↑ Back to top

Quick Reference for Harm Reduction

• Walker AF, Marakis G, Christie S, Byng M. Magnesium bioavailability from oral preparations (Magnesium Research)
  Comparative bioavailability study of magnesium forms showing glycinate/chelated superiority and reduced GI effects.
• RollSafe.org research team MDMA (Molly/Ecstasy) Supplements – RollSafe.org
  Most comprehensive public compilation of MDMA supplement research with citations to primary studies.
• Psychedelic Support editorial team Supplements to Reduce Side Effects of MDMA (Psychedelic Support)
  Clinical-grade summary of MDMA supplement evidence including dosing recommendations with research citations.

↑ Back to top